前列腺特异性膜抗原无线电配体治疗在患有侵袭性变异性前列腺癌的患者中
Moein Moradpour1, Abuzar Moradi Tuchayi1, Surekha Yadav1
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
概括
与非AVPC患者相比,接受前列腺特异性膜抗原 (PSMA) 向放射性联体疗法 (RLT) 的侵袭性变异性前列腺癌 (AVPC) 患者表现出类似的PSA降低,但整体存活率更差. 这些发现表明,如果PSMA表达足够,PSMA RLT可能是AVPC的可行选择.
科学领域:
- 在瘤学瘤学.
- 核医学是一种核医学.
- 泌尿生殖系统的癌症
背景情况:
- 侵袭性前列腺癌 (AVPC) 具有高风险特征,通常用化疗治疗.
- 前列腺特异性膜抗原 (PSMA) 向的放射性联体疗法 (RLT) 是一种新兴的治疗方法,用于转移性割抵抗性前列腺癌 (mCRPC).
研究的目的:
- 评估使用PSMA RLT治疗AVPC患者的结局.
- 为了比较AVPC患者的治疗反应和存活率与接受PSMA RLT的非AVPC患者.
主要方法:
- 对82名AVPC患者和3个学术中心接受PSMA RLT的非AVPC患者的配对队列进行了回顾性研究.
- AVPC患者被分为临床病理学 (AVPC-C) 和分子特征 (AVPC-MS) 组.
- 分析了前列腺特异性抗原 (PSA) 反应,PSA无进展生存率 (PFS),总生存率 (OS) 和成像参数 (SUV平均值,总瘤体积).
主要成果:
- 在AVPC (62.1%) 和非AVPC (60.7%) 组中,实现≥50%PSA降低的患者的百分比是相似的.
- 中位数PSA PFS为AVPC的3.2个月,而非AVPC的4.2个月 (P=0.10).
- 与非AVPC患者 (13.3个月) 相比,AVPC患者的中位寿命显著较短 (11.8个月) (P=0.04). 在AVPC-MS和AVPC-C亚组之间没有观察到显著的OS差异.
结论:
- 与非AVPC患者相比,接受PSMA RLT治疗的AVPC患者的整体存活率明显降低.
- 尽管OS较差,但AVPC患者的PSA应答率与PSMA RLT相似.
- 对于具有足够PSMA表达的AVPC患者,应考虑PSMA RLT.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...